Home › Proteins › Mammalian › Cell Line Development
Mammalian Cell Line Development
Develop a mammalian expression system designed for manufacturability, scalability and smooth transfer into process development. 53Biologics supports CHO, HEK and other mammalian programs through a partner-enabled CLD model.
Cell line development sets the expression foundation every downstream stage of your mammalian pipeline builds on.
01
Cell Line Development
02
Cell Banking
03
Process Development
04
Analytical Support
05
Manufacturing
06
Fill & Finish
This service is available also for:
Overview
Mammalian Cell Line Development Built for the Next Step
Selecting the right production cell line is one of the most critical decisions in the development of a recombinant protein. Cell line productivity, stability and manufacturability directly influence process performance, product quality and long-term commercial success.
At 53Biologics, we define the optimal cell line development strategy around your protein, coordinating every stage, from host selection and clone generation to cell banking and GMP manufacturing. By combining our technical oversight with a network of qualified technology partners, we provide access to proven mammalian cell line development capabilities while maintaining a single point of contact throughout your program.
Whether your goal is preclinical material, clinical supply or commercial manufacturing, we ensure your production cell line is developed with the next manufacturing stages in mind.
Our Expertise in Cell Line Development
Platform Fit & Risk Assessment
Evaluation of CHO-derived, HEK293 and other suitable mammalian systems against your molecule’s expression, structural and product quality requirements. Early platform selection helps reduce avoidable development and scale-up risks.
Clear Development Decisions
Predefined selection criteria and comparative data support transparent, evidence-based decisions throughout the program. Clients gain a clear understanding of why a clone is recommended and which risks require further evaluation.
Transfer-Ready Technical Package
The final development package consolidates cell line history, performance data, analytical results and recommended next steps. This creates a stronger starting point for process development, cell banking and future GMP transfer.
Process
Our Mammalian Cell Line Development Workflow
01
Project
Definition
Together, we review your molecule, target product profile, expression requirements and development objectives to define the most suitable mammalian cell line development strategy and selection criteria.
02
Transfection & Pool Creation
Host cells are transfected with the selected expression construct to generate stable cell pools. Pools are screened for productivity, growth performance and initial product quality to identify the strongest starting populations.
03
Single-Cell
Cloning
High-performing pools undergo single-cell cloning to isolate monoclonal production cell lines. Individual clones are expanded and evaluated for productivity, growth, viability and manufacturability.
04
Stability
Study
Selected clones are assessed over an extended culture period to confirm stable growth and recombinant protein expression. Productivity, cell performance and relevant product quality attributes are monitored throughout the study.
05
Final Report & Clone Selection
A comprehensive report summarizes the development workflow, analytical results and comparative clone performance. The most suitable production clone is recommended based on productivity, stability, growth and future manufacturing potential.
Which Mammalian Expression System Fits Your Protein?
There is no single mammalian cell line that is right for every protein. Productivity matters, but so do product quality, post-translational modifications, stability, scalability, regulatory strategy and the commercial conditions associated with the selected platform. We help evaluate these factors early, so your program does not commit to a platform based only on initial expression results and later face unexpected licensing, process development or manufacturing constraints.
| Expression Platform | Best Suited For | Key Advantages | Available Technologies |
|---|---|---|---|
| CHO-derived Platforms | Monoclonal antibodies, biosimilars and recombinant proteins requiring scalable commercial manufacturing. | Industry-standard platform with proven regulatory acceptance, robust scalability and high productivity. Advanced options support high-yield expression and glycoengineering. | CHOExpress®, CHOFlow®, CHOnamite® |
| HEK293-derived Platforms | Complex recombinant proteins, transient expression and proteins requiring human-like post-translational modifications. | Excellent expression of difficult proteins, authentic glycosylation and rapid development timelines. Suitable for transient and stable expression. | HEKExpress®, HEK2Express® |
| Specialized Mammalian Platforms | Challenging molecules requiring customized expression strategies or specific glycosylation profiles. | Alternative mammalian hosts selected according to product characteristics, expression performance and quality requirements. | GlycoExpress® (GEX®) and other qualified expression platforms |
The final expression platform is selected according to the protein’s structural complexity, quality attributes, manufacturing strategy and regulatory objectives. Additional mammalian platforms can be evaluated upon request.
Why Choose 53Biologics for Mammalian Cell Line Development
A Strategy Shaped Around Your Molecule
We work closely with your team to define the host, platform and selection criteria around your protein’s structural, quality and manufacturing requirements. The program is shaped around the molecule, not a predefined platform.
Scientific Decisions You Can Rely On
Productivity is assessed alongside stability, growth performance, product quality and manufacturability. This balanced approach helps avoid advancing a high-producing clone that may introduce challenges during process development or scale-up.
Flexibility Without Future Constraints
Access to CHO, HEK and other suitable platforms through specialized partners allows us to evaluate different technical routes. Licensing conditions, technology access and future manufacturing requirements are considered early to reduce unexpected limitations or costs.
Continuity Beyond Cell Line Development
The selected clone is supported by a clear, transfer-ready technical package for cell banking, process development and GMP manufacturing. Keeping these stages connected helps preserve knowledge and reduce the risks associated with changing partners.
Support
Frequently Asked Questions
Common questions about our mammalian cell line development services. Can’t find what you need? Talk to our team.
Which mammalian expression systems do you support?
We support projects based on CHO, HEK and other suitable mammalian expression platforms, selecting the host according to your protein's structural requirements, productivity targets, and intended application.
Can you work with an existing production cell line?
Yes. We can integrate existing client-developed production cell lines into cell banking, process development, and GMP manufacturing workflows.
Can 53Biologics develop a new production cell line?
Yes. We coordinate mammalian cell line development programs from host selection through clone evaluation and selection, providing a seamless transition into manufacturing.
How do you select the best clone?
Clone selection considers productivity, genetic stability, product quality attributes, and manufacturing performance to identify candidates suitable for long-term production.
Can you generate Master and Working Cell Banks after cell line development?
Yes. Once the production clone has been selected, we support qualified Master and Working Cell Bank generation, characterization, long-term storage and integration into GMP manufacturing.
Request a Quote for Your Mammalian Cell Line Development Project
Tell us about your molecule and target product profile — our team will get back to you as soon as possible.
Latest News
Latest From Our Blog
Insights, protocols and perspectives from our scientific team.